CLINICAL AND LABORATORY ASSESSMENT OF A NEW PROGESTATIONAL AGENT.

article OA: green CC0
📄 Open PDF View on OpenAlex View on PubMed
AI-generated summary by gemini-2.5-flash-lite, 2026-08-03

Megestrol, a new progestational agent, effectively controlled menstrual function and inhibited ovulation when combined with ethinyl estradiol, with minimal side effects and no observed toxicity.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Studies of the effects of megestrol (6-methyl, 6-dehydro, 17alpha-acetoxy progesterone) on human subjects indicated that this drug is a potent, orally effective progestational agent. The progestational effect was enhanced by estrogen. When combined with ethinyl estradiol satisfactory control of menstrual function and inhibition of ovulation were achieved. Increasing doses of this combination were effective in four patients with endometriosis. Side effects of the drug were minimal. No toxic effects on adrenal, hepatic or hematopoietic function were noted.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

17-Ketosteroids Adrenal Cortex Hormones Amenorrhea Biomedical Research Endometriosis Estrogens Ethinyl Estradiol Megestrol Menstruation Ovulation Pathology Pharmacology Pregnanediol Progesterone Progestins Toxicology Female Humans

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-24T06:08:07.662257+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-14T05:59:32.213054+00:00
License: CC0 · commercial use OK